164 related articles for article (PubMed ID: 16755104)
21. Extended adjuvant aromatase inhibition after sequential endocrine therapy (DATA): a randomised, phase 3 trial.
Tjan-Heijnen VCG; van Hellemond IEG; Peer PGM; Swinkels ACP; Smorenburg CH; van der Sangen MJC; Kroep JR; De Graaf H; Honkoop AH; Erdkamp FLG; van den Berkmortel FWPJ; de Boer M; de Roos WK; Linn SC; Imholz ALT; Seynaeve CM;
Lancet Oncol; 2017 Nov; 18(11):1502-1511. PubMed ID: 29031778
[TBL] [Abstract][Full Text] [Related]
22. Treatment trends and factors associated with survival in T1aN0 and T1bN0 breast cancer patients.
Kennedy T; Stewart AK; Bilimoria KY; Patel-Parekh L; Sener SF; Winchester DP
Ann Surg Oncol; 2007 Oct; 14(10):2918-27. PubMed ID: 17638060
[TBL] [Abstract][Full Text] [Related]
23. Basic research for hormone-sensitivity of breast cancer.
Hayashi S; Yamaguchi Y
Breast Cancer; 2006; 13(2):123-8. PubMed ID: 16755105
[TBL] [Abstract][Full Text] [Related]
24. Adjuvant treatment of breast cancer.
Akerley WL
R I Med; 1995 Sep; 78(9):250-3. PubMed ID: 7579720
[No Abstract] [Full Text] [Related]
25. Management of breast cancer in very young women.
Freedman RA; Partridge AH
Breast; 2013 Aug; 22 Suppl 2():S176-9. PubMed ID: 24074783
[TBL] [Abstract][Full Text] [Related]
26. Disease related indicators for a proper choice of adjuvant treatments.
Hayes DF
Breast; 2011 Oct; 20 Suppl 3():S162-4. PubMed ID: 22015287
[TBL] [Abstract][Full Text] [Related]
27. Optimal systemic therapy for premenopausal women with hormone receptor-positive breast cancer.
Jankowitz RC; McGuire KP; Davidson NE
Breast; 2013 Aug; 22 Suppl 2():S165-70. PubMed ID: 24074781
[TBL] [Abstract][Full Text] [Related]
28. Postmenopausal women with hormone receptor-positive breast cancer: balancing benefit and toxicity from aromatase inhibitors.
Ingle JN
Breast; 2013 Aug; 22 Suppl 2():S180-3. PubMed ID: 24074784
[TBL] [Abstract][Full Text] [Related]
29. Can exemestane improve adjuvant treatment for postmenopausal women with primary breast cancer?
Hutchinson L
Nat Clin Pract Oncol; 2004 Nov; 1(1):24-5. PubMed ID: 16264795
[No Abstract] [Full Text] [Related]
30. Commentary: optimal adjuvant endocrine therapy of postmenopausal breast cancer.
Cunnick G; Mokbel K
Int J Fertil Womens Med; 2005; 50(5 Pt 1):197-8. PubMed ID: 16468468
[TBL] [Abstract][Full Text] [Related]
31. Aromatase inhibitors and breast cancer prevention.
Litton JK; Arun BK; Brown PH; Hortobagyi GN
Expert Opin Pharmacother; 2012 Feb; 13(3):325-31. PubMed ID: 22242911
[TBL] [Abstract][Full Text] [Related]
32. [Consensus Meeting of the 9th International Conference on Primary Therapy of Early Breast Cancer (St. Gall, January 26-29, 2005)].
Thürlimann B; Senn HJ
Gynakol Geburtshilfliche Rundsch; 2005 Jun; 45(3):143-6. PubMed ID: 15990439
[TBL] [Abstract][Full Text] [Related]
33. Using aromatase inhibitors in the neoadjuvant setting: evolution or revolution?
Freedman OC; Verma S; Clemons MJ
Cancer Treat Rev; 2005 Feb; 31(1):1-17. PubMed ID: 15707700
[TBL] [Abstract][Full Text] [Related]
34. Letrozole : in postmenopausal hormone-responsive early-stage breast cancer.
Scott LJ; Keam SJ
Drugs; 2006; 66(3):353-62. PubMed ID: 16526826
[TBL] [Abstract][Full Text] [Related]
35. The nature of tamoxifen action in the control of female breast cancer.
Kodama M; Kodama T
In Vivo; 2001; 15(4):319-25. PubMed ID: 11695224
[TBL] [Abstract][Full Text] [Related]
36. [Intensification of a diffuse chronic pain syndrome by the introduction of an aromatase inhibitor].
Nemitz N; Kurmann PT; Van Linthoudt D
Praxis (Bern 1994); 2008 Feb; 97(3):137-41. PubMed ID: 18549014
[TBL] [Abstract][Full Text] [Related]
37. Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women.
Gibson LJ; Dawson C; Lawrence DH; Bliss JM
Cochrane Database Syst Rev; 2007 Jan; (1):CD003370. PubMed ID: 17253488
[TBL] [Abstract][Full Text] [Related]
38. Addressing the future: combination with targeted therapies, adjuvant setting and beyond.
Goss PE
Anticancer Drugs; 2008 Mar; 19 Suppl 2():S3-5. PubMed ID: 18337641
[TBL] [Abstract][Full Text] [Related]
39. [Adjuvant treatment in hormone receptor positive breast cancer].
Streng H
MMW Fortschr Med; 2010 Oct; 152(41):37-9. PubMed ID: 21090375
[No Abstract] [Full Text] [Related]
40. Adjuvant hormonal therapy.
Tamaki Y; Miyoshi Y; Noguchi S
Breast Cancer; 2002; 9(3):185-9. PubMed ID: 12185327
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
